Close Menu

NEW YORK (GenomeWeb) – Qiagen said today that it has initiated a clinical development program with Novartis for a molecular companion diagnostic to guide the use of a Novartis investigational PI3K inhibitor in certain breast cancer patients.

Specifically, the proposed CDx would guide use of Novartis' BYL719 (alpelisib) in combination with fulvestrant for men and postmenopausal women with PIK3CA-mutated, hormone receptor-positive, EGFR receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
24
Sponsored by
SCHOTT MINIFAB

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.